Skip to main content
Premium Trial:

Request an Annual Quote

Prescient Metabiomics, Harvard Partner on Colon Cancer Biomarker Research

NEW YORK — Prescient Metabiomics said on Tuesday that it has partnered with the Harvard TH Chan School of Public Health to investigate microbiome biomarkers in colon cancer.

Under the terms of the deal, Prescient Metabiomics and collaborators at the Harvard Chan Microbiome in Public Health Center will study the use of microbial biomarkers to identify precancerous adenomas and carcinomas in the colon. The effort will initially use bioinformatic approaches to analyze colorectal cancer cases across different populations, focusing on prevalent gut microbial biomarkers for the disease.

"The ongoing research collaboration will further enhance diagnostic screening for colon cancer," Keri Donaldson, CEO of Prescient Metabiomics parent firm Prescient Medicine, said in a statement. "Offering a non-invasive alternative to colonoscopies that screen for colorectal adenomas and carcinomas could represent a paradigm shift in [colorectal cancer] screening driven by the microbiome."

In late 2019, Carlsbad, California-based Prescient Metabiomics began working with OraSure Technologies subsidiary CoreBiome on a microbial-based colon cancer screening test.